Cod Liver/Fish Oil supplements assessed using repeated measures are prospectively and cross-sectionally associated with Cognitive Performance tests in a population based cohort
View / Open Files
Authors
Lentjes, MAH
Hayat, S
Brayne, C
Khaw, KT
Publication Date
2017Journal Title
PROCEEDINGS OF THE NUTRITION SOCIETY
Conference Name
Diet, nutrition and mental health and wellbeing
ISSN
0029-6651
Publisher
Cambridge University Press (CUP)
Volume
76
Issue
OCE1
Pages
E1-E1
Type
Conference Object
Metadata
Show full item recordCitation
Lentjes, M., Hayat, S., Brayne, C., & Khaw, K. (2017). Cod Liver/Fish Oil supplements assessed using repeated measures are prospectively and cross-sectionally associated with Cognitive Performance tests in a population based cohort. PROCEEDINGS OF THE NUTRITION SOCIETY, 76 (OCE1), E1-E1. https://doi.org/10.1017/S0029665117000015
Abstract
Dementia is a condition mainly affecting older people. Non-modifiable risk factors include age and genetic factors; however, lifelong,
modifiable -and largely behavioural- risk factors may be associated with cognitive function and dementia risk (1). Changes in these risk factors
may occur during a person’s life course. There has been much interest in fish consumption in relation to dementia(2) as well as cardiovascular
disease risk(3), suggesting a potential biological pathway for omega-3 polyunsaturated fatty acids (n-3 PUFA). Fish intake has been below
SACN recommendations in the UK(4); whereas cod liver oil (CLO) is the most popular supplement consumed and contributes 50 % to over-
all n-3 PUFA intake(5) . We studied cross-sectional as well as prospective associations between n-3 PUFA containing supplements and per-
formance on cognitive tests in the European Prospective Investigation into Cancer, based in Norfolk (UK). ....
Identifiers
External DOI: https://doi.org/10.1017/S0029665117000015
This record's URL: https://www.repository.cam.ac.uk/handle/1810/279552
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.